Leerink Partners Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $997
Leerink Partners analyst David Risinger maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Market Perform and raises the price target from $835 to $997.
Share
Why It Matters
An analyst raised their price guess for Regeneron from $835 to $997. They still think the stock is fairly priced, so watch for real business news to decide what happens next.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.